NO20065326L - Aminopyridine derivatives as selective dopamine D3 agonists - Google Patents

Aminopyridine derivatives as selective dopamine D3 agonists

Info

Publication number
NO20065326L
NO20065326L NO20065326A NO20065326A NO20065326L NO 20065326 L NO20065326 L NO 20065326L NO 20065326 A NO20065326 A NO 20065326A NO 20065326 A NO20065326 A NO 20065326A NO 20065326 L NO20065326 L NO 20065326L
Authority
NO
Norway
Prior art keywords
disorder
agonists
compounds
sexual dysfunction
female
Prior art date
Application number
NO20065326A
Other languages
Norwegian (no)
Inventor
Charlotte Moira Norfo Allerton
David Hepworth
Andrew Simon Cook
Duncan Charles Miller
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34970000&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20065326(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0411891A external-priority patent/GB0411891D0/en
Priority claimed from GB0412463A external-priority patent/GB0412463D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of NO20065326L publication Critical patent/NO20065326L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Det beskrives forbindelser av formel (I) som er en klasse dopamin agonister, nærmere bestem en klase agonister som er selektive for D3 over D2. Disse forbindelser er nyttige for behandling av og/eller hindring av seksuell dysfunksjon, for eksempel kvinnelig seksuell dysfunksjon (FSD), spesiell kvinnelig opphisselses-forstyrrelse (FSAD), hypoaktiv seksuell begjæringsforstyrrelse (HSDD), mangel på interesse på sex, kvinnelig orgasmeforstyrrelse (FOD; manglende evne til å oppnå orgasme); og mannlig seksuell dysfunksjon, spesielt mannlig erektil dysfunksjon (MED). Mannlig seksuell dysfunksjon som referert heri, er ment å inkludere ejakulasjonsforstyrrelse så som for tidlig ejakulering, anorgasmi (manglende evne til å oppnå orgasme) eller begjæringsforstyrrelser så som hypoaktiv seksuell begjær-forstyrrelse (HSDD; mangel på interesse for sex). Disse forbindelser er også nyttige i å behandle nevropsykiatriske forstyrrelser og nevrodegenerative forstyrrelser.Compounds of formula (I) which are a class of dopamine agonists are disclosed, more particularly a class of agonists which are selective for D3 over D2. These compounds are useful for treating and / or preventing sexual dysfunction, such as female sexual dysfunction (FSD), special female arousal disorder (FSAD), hypoactive sexual desire disorder (HSDD), lack of interest in sex, female orgasmic disorder (FOD) failure to achieve orgasm); and male sexual dysfunction, especially male erectile dysfunction (MED). Male sexual dysfunction as referred to herein is intended to include ejaculation disorder such as premature ejaculation, anorgasmia (inability to achieve orgasm), or desire disorders such as hypoactive sexual desire disorder (HSDD; lack of interest in sex). These compounds are also useful in treating neuropsychiatric disorders and neurodegenerative disorders.

NO20065326A 2004-05-27 2006-11-20 Aminopyridine derivatives as selective dopamine D3 agonists NO20065326L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0411891A GB0411891D0 (en) 2004-05-27 2004-05-27 New aminopyridine derivatives and their use as pharmaceuticals
GB0412463A GB0412463D0 (en) 2004-06-03 2004-06-03 New aminopyridine derivatives and their use as pharmaceuticals
PCT/IB2005/001554 WO2005115985A1 (en) 2004-05-27 2005-05-17 Aminopyridine derivatives as selective dopamine d3 agonists

Publications (1)

Publication Number Publication Date
NO20065326L true NO20065326L (en) 2006-12-19

Family

ID=34970000

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065326A NO20065326L (en) 2004-05-27 2006-11-20 Aminopyridine derivatives as selective dopamine D3 agonists

Country Status (21)

Country Link
EP (1) EP1758862A1 (en)
JP (1) JP4198183B2 (en)
AP (1) AP2006003824A0 (en)
AR (1) AR049548A1 (en)
AU (1) AU2005247699A1 (en)
BR (1) BRPI0511571A (en)
CA (1) CA2567935C (en)
EA (1) EA200601982A1 (en)
EC (1) ECSP067029A (en)
GT (1) GT200500125A (en)
IL (1) IL179314A0 (en)
MA (1) MA28607B1 (en)
MX (1) MXPA06013786A (en)
NL (1) NL1029139C2 (en)
NO (1) NO20065326L (en)
PA (1) PA8635101A1 (en)
PE (1) PE20060366A1 (en)
SV (1) SV2005002129A (en)
TW (1) TW200609216A (en)
UY (1) UY28925A1 (en)
WO (1) WO2005115985A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0502509D0 (en) 2005-02-07 2005-03-16 Pfizer Ltd Novel salt form of a dopamine agonist
CN102317291B (en) 2009-02-13 2015-02-11 拜耳知识产权有限责任公司 Fused pyrimidines
MX355697B (en) * 2010-04-12 2018-04-27 Supernus Pharmaceuticals Inc Methods for producing viloxazine salts and novel polymorphs thereof.
BR112013034074B1 (en) 2011-06-30 2021-02-23 Donaldson Company, Inc filter cartridge and crankcase ventilation filter assembly
GB2543296A (en) * 2015-10-13 2017-04-19 Indivior Uk Ltd Dopamine D3 receptor antagonists having a morpholine moiety
TWI755255B (en) 2016-07-20 2022-02-11 瑞士商諾華公司 Aminopyridine derivatives and their use as selective alk-2 inhibitors
AU2020270992A1 (en) * 2019-04-12 2021-10-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services D3 receptor agonist compounds; methods of preparation; intermediates thereof; and methods of use thereof
KR20220107213A (en) 2019-11-22 2022-08-02 인사이트 코포레이션 Combination therapy comprising an ALK2 inhibitor and a JAK2 inhibitor
CN115968289A (en) 2020-06-16 2023-04-14 因赛特公司 ALK2 inhibitors for the treatment of anemia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077290A (en) * 1990-10-11 1991-12-31 Merck & Co., Inc. Morpholine derivatives compositions and use
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction
JP3889775B2 (en) * 2002-12-10 2007-03-07 ファイザー・インク I. A. Morpholine derivatives for use as dopamine agonists in the treatment of sexual dysfunction

Also Published As

Publication number Publication date
PA8635101A1 (en) 2006-05-16
EA200601982A1 (en) 2007-04-27
SV2005002129A (en) 2005-12-13
PE20060366A1 (en) 2006-05-15
JP2008500331A (en) 2008-01-10
WO2005115985A1 (en) 2005-12-08
AP2006003824A0 (en) 2006-12-31
MA28607B1 (en) 2007-05-02
BRPI0511571A (en) 2008-01-02
EP1758862A1 (en) 2007-03-07
AU2005247699A1 (en) 2005-12-08
TW200609216A (en) 2006-03-16
MXPA06013786A (en) 2007-01-25
NL1029139A1 (en) 2005-11-30
UY28925A1 (en) 2005-12-30
AR049548A1 (en) 2006-08-16
CA2567935C (en) 2009-10-27
ECSP067029A (en) 2006-12-29
NL1029139C2 (en) 2006-06-19
IL179314A0 (en) 2007-03-08
CA2567935A1 (en) 2005-12-08
JP4198183B2 (en) 2008-12-17
GT200500125A (en) 2006-01-10

Similar Documents

Publication Publication Date Title
NO20065326L (en) Aminopyridine derivatives as selective dopamine D3 agonists
GEP20217265B (en) Glp-1 receptor agonists and uses thereof
MX2021012669A (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol- 5-yl)-pyridin-3-yl)methoxy)benzaldehyde.
ATE301652T1 (en) PIPERAZINE DERIVATIVES AS AGONISTS OF THE MELANOCORTIN RECEPTOR
GEP20146131B (en) Carbazole compounds and therapeutic uses thereof
MA40481A (en) PYRIDIN-2- (1H) -ONE-QUINOLINONE DERIVATIVES AS MUTANT ISOCITRATE DEHYDROGENASE INHIBITORS
ATE342057T1 (en) MELANOCORTIN RECEPTOR AGONISTS
MX2012001773A (en) System and method for servicing a wellbore.
PH12015501585A1 (en) Manufacturing process for pyrimidine derivatives
SG2013049648A (en) Chlorination of carbohydrates and carbohydrate derivatives
CL2012003132A1 (en) Compounds derived from heteroaryl-cyclohexyl-tetraazabenzo [e] azulenes, vla receptor antagonists; Preparation process; pharmaceutical composition; and its use for the prevention or treatment of dysmenorrhea, male or female sexual dysfunction, hypertension and liver cirrhosis, among others.
NO20092143L (en) Use of testosterone and a 5-HT1A agonist in the treatment of sexual dysfunction
GT200600207A (en) PROCESS FOR THE SYNTHESIS OF ORGANIC COMPOUNDS
PE20220811A1 (en) PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONIL)-PYRIDIN-2-IL]-BENZAMIDE HEMISUCCINATE AND PREPARATION OF ACETATE 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-IL]-BENZAMIDE
NO20065328L (en) Indazole and indolone derivatives, and their use as pharmaceutical agents.
MA33500B1 (en) Pyrazole derivatives, their preparation and use in treatment
EA200801211A1 (en) DERIVATIVES 9-CHLOR-15-PROSTAGLANDINA, METHOD FOR THEIR PRODUCTION AND USE IN DRUGS
TW200716555A (en) Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
MX2011005971A (en) Novel polymorphic forms of an azabicyclo-trifluoromethyl benzamide derivative.
MA46064A (en) PYRIDIN-2- (1H) -ONE-QUINOLINONE DERIVATIVES AS ISOCITRATE DEHYDROGENASE INHIBITORS
DOP2005000095A (en) NEW DERIVATIVES OF AMINOPIRIDINE AND ITS USE AS PHARMACOS
MX2012014968A (en) Fixed doses of a tadalafil and dapoxetine pharmaceutical combination.
DOP2005000093A (en) NEW DERIVATIVES OF INDAZOL AND INDOLONA AND ITS USE AS PHARMACEUTICAL PRODUCTS
UA92523U (en) Method for treating contusion of cerebellar hemisphere by grafting tissue of olfactory bulb
TW200716565A (en) Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents